Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

New Homeopathic Spray Offers Fast, Short-Term Relief From Nicotine Cravings
With rising taxes and increasing restrictions on smoking and tobacco, smokers looking for temporary relief from cravings and withdrawal symptoms during periods when they couldn"t smoke, or chose not to, were out of luck. But a new breed of short-term cessation treatment -- based on age-old homeopathic practices -- promises to help smokers manage cravings on-the-spot, when lighting up isn"t an option.
generic viagra online
Can-Fite Announces Positive Results From Its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) With CF101
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today that its 80-patient Phase II clinical study using CF101 to treat patients with moderate to severe Dry Eye Syndrome had successfully met the primary efficacy endpoint. Patients in this masked study were randomly assigned to either 1 mg of CF101 or matching placebo; drug was taken orally as a monotherapy for 12 weeks. The 12 week duration is one that Can-Fite has used in other trials of CF101 as an anti-inflammatory agent, and is similarly a common one for Phase II trials of Keratoconjunctivitis Sicca. The patient group receiving CF101 demonstrated statistically significant improvement in superficial punctate keratitis, relative to the placebo group, as measured by fluorescein staining. This sensitive and prevalent measure of corneal disease was prospectively defined as a primary study endpoint, thus demonstrating the ability of orally administered CF101 to exert beneficial effects on ocular surface inflammation. An improvement in additional study parameters was also observed. CF101 was safe and well tolerated during the study period.
News of the day
Journal Of Foot & Ankle Surgery(R) Now Abstracted And Indexed By Thomson Reuters
Elsevier announced that the Journal of Foot & Ankle Surgery (JFAS), the Official Journal of the American College of Foot and Ankle Surgeons (http://www.acfas.org), has been accepted for coverage by multiple Thomson Reuters abstracting and indexing services, including Journal Citation Reports®.
Nutrition

Global Vaccine Initiative Wins Support From Italian, Canadian, Russian Finance Ministers

Finance ministers from Italy, Canada and Russia Friday voiced their support for a program aimed at lowering the prices of vaccines for developing countries, the AFP/Google.com reports. "The Advanced Market Commitment (AMC) programme was first outlined in 2007 and will encourage pharmaceutical companies to invest in research for vaccines against deadly diseases by promising to buy the vaccines at a fixed price," the AFP/Google.com writes (AFP/Google.com, 6/12). The program - which is funded by Italy, the U.K., Canada, Russia, Norway and the Bill & Melinda Gates Foundation - will start by focusing on a vaccine for pneumococcal disease (Kaiser Daily Global Health Policy Report, 6/12). The finance ministers at a G8 meeting in Italy on Friday signed off on the new project, which is estimated to make the current pneumococcal vaccine available for $3.50 in developing countries compared to $70 in developed countries (AFP/Google.com, 6/12). "Italy is proud to support the AMC initiative: immunisation is an investment in human capital that fosters long-term economic development," Italian Finance Minister Giulio Tremonti said in a written statement (AFP/Google.com, 6/12). "If this pilot project works out, well, then, this will start out I think a wave of financing vaccines in the poorest countries in the world," Canadian Finance Minister Jim Flaherty said (Akin, Canwest News Service/The Gazette, 6/14). Some groups are not convinced AMC will lead vaccine prices for developing countries to drop, including Medicins Sans Frontieres (MSF) which said developing world vaccine producers should be involved in the process, according to AFP/Google.com. "It"s only if developing country manufacturers enter the market that we can expect prices to come down to more affordable levels in the future," Laurent Gadot, a health economist at MSF, said in a statement (AFP/Google.com, 6/12). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009